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all survival of the patients was found.  Conclusions: MTAP ex-
pression is retained in PAs and is not an outcome predictor 
for these tumors. Nevertheless, a subset of patients with PAs 
exhibiting a loss of MTAP could potentially benefit from treat-
ment with specific chemotherapy, especially when lesions 
are recurrent or surgical resection is not recommended. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Pilocytic astrocytoma (PA) is the commonest brain tu-
mor in children and teenagers in the USA  [1] and Brazil 
 [2, 3] . PAs are considered benign, exhibiting an indolent 
nature. PAs in adults are rare and usually more aggressive 
 [4] . Although the majority of cases occur as sporadic dis-
ease, PAs can arise in the heredity context of type 1 neu-
rofibromatosis (Nf1)  [5–7] . Nf1-PAs are usually less ag-
gressive and located at extracerebellar sites  [8] . The over-
all prognosis for PAs is good, but in some cases they are 
aggressive, leading to death  [9–11] . Extension of resec-
tion and high mitotic activity are key factors related to a 
poor prognosis in PAs  [10, 11] .
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 Abstract 
 Background/Objectives: Pilocytic astrocytomas (PAs) are the 
most frequent astrocytomas in children and adolescents.  Me-
thilthioadenosine phosphorylase  (MTAP) is a tumor-suppres-
sor gene, the loss of expression of which is associated with a 
poor prognosis and better response to specific chemothera-
py in leukemia and non-small-cell lung cancer. The expres-
sion of MTAP in brain tumors remains largely unknown and 
its biological role in PA is still unexplored. Our aims were to 
describe the immunohistochemical MTAP expression in a se-
ries of PAs and relate it to the clinicopathological features of 
the patients.  Methods: We assessed MTAP expression on im-
munohistochemistry in 69 pediatric and adult patients with 
PA in a tissue microarray platform.  Results: Retained expres-
sion of MTAP was seen in >85% of the tumors compared to in 
the nonneoplastic adjacent tissue. Only 3 supratentorial tu-
mors showed a complete loss of MTAP expression. No sig-
nificant association with clinicopathological features or over-
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 The molecular pathogenesis of PAs has been extensive-
ly studied, particularly the constitutive activation of the 
mitogen-activated protein kinase (MAPK) pathway 
through  BRAF  proto-oncogene alterations  [9, 12–21] , such 
as  KIAA1549 - BRAF  (K:B) fusion (in up to 80% of cases, 
mainly in cerebellar lesions) and V600E  BRAF point muta-
tion (in 10% of cases, more frequent in supratentorial le-
sions)  [9, 22, 23] . Recently, point mutations in the  fibro-
blast growth factor receptor 1  (FGFR1)  gene ,  a MAPK up-
stream receptor , were described in extracerebellar tumors 
as an alternative mechanism for MAPK activation  [20] .
 Canonically, the MAPK pathway leads to increased 
cell proliferation; however, it may also cause oncogene-
induced senescence in cells  [9] . Oncogene-induced se-
nescence restricts the progression of benign tumors, such 
as melanocytic nevi and PAs, in response to V600E  BRAF 
mutation  [19, 24] . In PAs, the ectopic expression of the 
V600E  BRAF mutation results in induction of the INK4a/
ARF locus, at 9p21, with subsequent overexpression of 
 p16 ,  a known senescence marker  [19, 25] , the loss of ex-
pression of which correlates with a shorter overall sur-
vival (OS) in sporadic PAs  [19] and a more aggressive 
course in some Nf1-PAs  [26] .
 Additionally, the 9p21 locus harbors the tumor sup-
pressor gene methylthioadenosine phosphorylase  (MTAP) 
 [27–29] , which is coexpressed with  p16 INK4a in various 
malignant tumors  [29–33] . Homozygous deletion of 
 MTAP upregulates de novo synthesis of purine (DNSP) 
and increases the proliferation of cancer cells  [29, 30] . In-
terestingly,  MTAP deletion increases the sensitivity of 
neoplastic cells to DNSP inhibitors such as methotrexate, 
 L -alanosine and pemetrexed  [27, 30] , particularly in leu-
kemia  [29, 30] and other solid tumors, e.g. in the lung, 
liver and breast  [30, 33–35] . In tumors of the central ner-
vous system, deletion and gene copy-number breakpoints 
of  MTAP have been reported in glioblastomas  [36, 37] , 
and in pediatric high-grade gliomas  [38] , respectively. 
However, none of these studies assessed MTAP expres-
sion by immunohistochemistry.
 The biological role of  MTAP in PAs is still unexplored. 
Our aims were to describe the immunohistochemical 
MTAP expression in a series of PAs and relate it to the 
clinicopathological features of the patients.
 Materials and Methods 
 Patients 
 From 1993 to 2013, 69 patients with PA were retrieved from the 
Pathology Department of the Barretos Cancer Hospital (HCB) and 
the Hospital Clinics of the Ribeirão Preto School of Medicine, Uni-
versity of São Paulo (HCRP), Brazil. Recurrent lesions from 5 pa-
tients, 1 with 2 relapsed lesions, were also analyzed, totalling 75 
samples. The patients were grouped according to gender, age (pe-
diatric:  ≤ 19 years old and adult:  ≥ 20 years old) and tumor location, 
i.e. cerebellar or extracerebellar. Patients with Nf1-PAs (n = 5) had 
confirmed clinical diagnosis of Nf1 by standardized criteria. Surgi-
cal resection was classified as gross total resection or partial resec-
tion, measured by immediate postsurgical CT scan  [39] . The out-
come of patients was categorized as favorable (stable, partially re-
sected lesions and totally resected lesions) or unfavorable 
(progressive or recurrent lesions, patients with a Karnofsky index 
<70 and/or death). An event was defined as the growth of a resid-
ual lesion or the recurrence of a totally resected lesion, detected 
clinically or by radiological exam. This study was approved by the 
Ethics Committees of both institutions (HCB/87362 and 
HCRP/212313).
 Tissue Microarray Construction 
 After review of the cases by two independent neuropatholo-
gists, two blocks of tissue microarray (TMA) were constructed 
from the formalin-fixed, paraffin-embedded samples, using the 
Beecher Instruments TM TMA platform, with 1.0-mm (HCB cases) 
and 1.5-mm (HCRP cases) needles. To represent the heterogeneity 
of the tumors, we obtained 1–8 cores from each case (average: 3.6 
cores/case). In 9 cases, adjacent nonneoplastic cerebellum was rep-
resented in the samples and included in the TMA.
 Western Blot Analysis 
 Cells from the SNB19 and MDA-MB231 cell lines, known to, 
respectively, express and not express MTAP  [40, 41] were grown 
in 25-cm 2 flasks (3 × 10 6 cells) to 80% cell confluence, scraped in 
standardized lysis buffer and then centrifuged to extract total 
protein. After electrophoresis, the blots were performed and in-
cubated with 5% nonfat dry milk in TBS-T for 1 h at room tem-
perature, with MTAP polyclonal antibody for 15 h at 4   °   C (Pro-
teintech, Chicago, Ill., USA; 1: 800) and β-actin (Cell Signaling, 
Boston, Mass., USA; 1: 5,000) as a control for 1 h at 4   °   C. Ulti-
mately, the blots were washed with TBS-T and incubated with 
anti-rabbit IgG (for MTAP) or anti-mouse IgG (for β-actin) 
HRP-linked antibody (Cell Signaling; 1: 5,000 for both antibod-
ies). Immunodetection was done with Amersham ECL Western 
blotting detection reagents in automatic ImageQuant LAS 4000 
mini (GE Healthcare).
 Immunohistochemical Analysis 
 To confirm the diagnosis of PA, we initially performed immu-
nohistochemical analysis of galectin-3  [42] and mutated IDH-1 
 [43] from the TMA slides. The reactions were accomplished using 
the established protocols for Ventana Benchmark Ultra platform 
(Ventana-Roche, Tucson, Ariz., USA) and the monoclonal anti-
bodies anti-galectin 3 (Diagnostic BioSystem, Pleasanton, Calif., 
USA; clone 9C4, dilution 1: 50), and anti-mutated IDH-1 (R132H; 
DIANOVA, Hamburg, Germany; clone H09, dilution 1: 50). The 
results were classified as negative or positive, when at least 10% of 
the tumor cells exhibited cytoplasmic positivity for each marker.
 For MTAP evaluation, we performed a manual immunohisto-
chemical assay on the TMA slides. Briefly, following sample dehy-
dration and antigen retrieval with a mixed buffer (citrate 10 m M /
EDTA 1 m M , pH 6.0) for 4 min at 125  °  C and 20 min at 90  °  C, the 
slides were incubated with the MTAP polyclonal antibody (Pro-
 Becker/Scapulatempo-Neto/Menezes/
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teintech; 1: 300) at room temperature overnight. Then slides were 
incubated with secondary antibody and streptavidin peroxidase, 
stained with 3,3 ′ diaminobenzidine chromogen and counter-
stained with hematoxylin.
 The subcellular localization (cytoplasmic and/or nuclear), ex-
tension and intensity of the reaction were further evaluated and 
scored. The extension of reaction was measured as: 0 (negative), 1 
( ≤ 25% of positive cells), 2 (25–50% of positive cells) or 3 ( ≥ 50% of 
positive cells). Intensity was measured as: 0 (negative), 1 (weak), 2 
(moderate) or 3 (strong). The sum of these parameters resulted in 
scores assumed as reduced expression (0–3) or retained expression 
(4–6). Endothelial positivity was the internal positive control. Ex-
ternal controls for both TMAs were normal liver and prostate, in 
addition to the cell-blocks of SNB19 and MDA-MB231 ( fig. 1 c–e). 
Average values were considered in cases with >1 core on the TMA.
 Statistical Analysis 
 The statistical analysis was performed using SPSS version 20 for 
Windows TM (IBM, Chicago, Ill., USA) with p < 0.05 considered 
statistically significant for the Fisher exact test, Pearson χ 2 test and 
McNemar test. Event-free survival (EFS) and OS were calculated 
by the Kaplan-Meier method.
 Results 
 The clinicopathological features of the series are sum-
marized in  table 1 . Patients’ age ranged from 0.3 to 53.4 
years old (median: 9.1 years old). Four pediatric patients 
died of disease (3 females and 1 male), 1 due to a recurrent 
tumor and 3 due to the progressive growth of lesions, 
within 1.7, 2.6, 6.5 and 10.7 years after the first surgery. 
Table 1. Clinicopathological features of patients with PA
Patients, n MTAP expression
0 ≤3 ≥4 p value
Patients (total) 69
Male 38 3 2 33 0.127
Female 31 0 5 26
Age group
Pediatric 60 3 6 51 1.0
Adult 9 0 1 8
Nf1
Yes 5 1 0 4 0.271
No 64 2 7 55
Location
Cerebellar 36 0 5 31 0.163
Extracerebellar 33 3 2 28
Extension of resection
Total 31 1 3 27 1.0
Partial 38 2 4 32
Outcome
Favorable 41 2 5 34 0.865
Unfavorable 28 1 2 25
Recurrence
Yes 5 0 1 4 0.525
No 26 1 2 23
Progression
Yes 17 1 0 16 0.145
No 21 1 4 16
Death
Yes 4 0 1 3 0.474
No 65 3 6 56
 Fig. 1.  a Immunohistochemical cytoplas-
mic expression of galectin-3. ×100.  b A 
sample of PA, negative for mutated IDH-1 
(400×).  c Western blot assay showing ex-
pression of MTAP in the SNB19 cell cul-
ture and no expression in the MDA-
MB-231 cell culture. Immunocytochemis-
try shows cytoplasmic expression of MTAP 
in the SNB19 cell lineage ( d ) and a lack of 
MTAP expression in the MDA-MB-231 
cell line ( e ). ×400. 
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The median EFS and OS for the entire cohort was 3.5 (0.1–
16.3) and 4.0 (0.6–16.6) years, respectively. Patients with 
relapsed tumors had a shorter EFS (0.1–10.7 years, median 
0.9) and OS (0.7–16.2 years, median 2.7). All the relapsed 
lesions maintained the histopathological criteria for PA.
 Galectin-3 was expressed in 95.7% of the series and all 
cases lacked mutated IDH-1 (R132H) expression ( fig. 1 a, 
b), confirming the diagnosis of PA.
 Following MTAP antibody validation by Western blot 
and immunocytochemistry in the SNB19 and MDA-
MB231 tumor cell lines ( fig. 1 ), we achieved adequate re-
sults in 67/69 of the primary lesions and in 5/6 of the re-
lapsed lesions. We observed cytoplasmic MTAP expres-
sion in 59/67 primary tumors (88.1%;  fig. 2 ). Ten cases 
(14.5%) presented reduced expression, including 3 that 
lost MTAP expression completely ( fig. 2 d).
 In the nonneoplastic cerebellum, Purkinje cells showed 
strong cytoplasmic positivity for MTAP, while the non-
neoplastic astrocytes were negative (score: 0) in 8/9 cases 
( fig. 2 b, c) and faintly positive in 1 case (score:  ≤ 3). The 
difference between neoplastic and nonneoplastic astro-
cytes was statistically significant in the Wilcoxon test (p = 
0.005). In contrast, there were no significant differences 
in MTAP expression between groups ( table 1 ).
 PAs in the optic pathways showed strongest MTAP 
expression (4/4 lesions, score: 6). The 3 tumors with a 
complete loss of MTAP expression were located in the 
cerebral hemispheres ( table 2 ). Among these patients, 1 
showed an Nf1-PA context and 1 had multiple recurrenc-
es (not analyzed in this study).
 The relapsed lesions displayed similar expression to 
their primary counterparts (p = 0.5, McNemar test). One 
patient had stronger expression in the relapsed lesion 
(score: 4 and 6) and the patient with 3 available samples 
presented decreasing MTAP expression over time (score: 
6, 5 and 4, respectively).
 Fig. 2. Patterns of immunohistochemical MTAP expression in ad-
jacent normal tissue and in PAs.  a A PA with piloid and round cells 
in a loose background with Rosenthal fibers. HE. ×400.  b Normal 
cerebellum, depicting strong reaction in Purkinje cells and astro-
cytes lacking MTAP expression. ×20.  Inset : strong cytoplasmic re-
action of Purkinje cells. ×200.  c Normal cerebellum-tumor transi-
tion – the tumor showed a moderate reaction. ×100.  d Tumor with 
loss of MTAP expression and positive endothelial reaction (ar-
rows). ×400.  e Moderate cytoplasmic MTAP staining. ×100. 
 f  Strong cytoplasmic MTAP reaction in piloid area of a PA. ×100. 
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 Finally, MTAP expression did not influenced the OS 
or EFS, as seen in the Kaplan-Meier curves (p = 0.645, p = 
0.736).
 Discussion 
 To the best of our knowledge, this is the first study to 
assess MTAP expression on immunohistochemistry in 
central nervous system tumors. We report that MTAP 
expression is retained in the majority of PAs. The few 
studies that have analyzed MTAP in gliomas reported 
 MTAP deletions and reduced mRNA expression in pedi-
atric  [38] and adult glioblastomas  [36, 37, 40, 44] . We also 
observed reduced MTAP tumor expression in a small 
number of infiltrative diffuse astrocytomas (i.e. WHO 
grades II–IV), with a trend towards lower expression in 
high-grade tumors (data not published), which suggests 
that the loss of MTAP expression is associated with in-
creased glioma malignancy.
 In this series of PAs, the loss of MTAP expression ob-
served in a few cases did not influence prognosis, and we 
could not confirm that MTAP is a predictor of outcome. 
In contrast, the loss of expression of the neighbor gene 
 p16 has a prognostic impact on PAs  [19] . Recently, it was 
described that the simultaneous loss of expression of  p16 
and MTAP determines shorter survival of patients with 
non-small-cell lung cancer  [45] .
 The normal distribution of MTAP in the central ner-
vous system is not properly defined  [46] . We describe that 
nonneoplastic astrocytes had virtually a complete loss of 
MTAP expression as opposed to the adjacent neoplastic 
astrocytes. In experimental studies on dementia, MTAP 
overexpression has been related to senescence and loss of 
neuroprotective function compared to normal astrocytes 
 [47, 48] . We therefore hypothesized that the adjacent cells 
play an essential role in the establishment of boundaries 
to the growth of PAs by avoiding these cells from senes-
cence, thereby maintaining their neuroprotective role. 
This, associated with the oncogene-induced senescence 
in the tumor cells, would help to explain the indolent be-
havior of PAs. Finally, the increased expression in spe-
cific cell subtypes, such as in the astrocytes of the optic 
nerve and retina, suggested by previous investigations 
 [46] , may explain why the tumors located in the optic 
pathways displayed stronger expression of MTAP in our 
series.
 The great interest in assessing the expression of MTAP 
in tumors arises from the therapeutic potential of DNSP 
inhibitors, such as methotrexate,  L -alanosine and peme-
trexed  [27] . It has been reported that a loss of MTAP ex-
pression sensitizes cancer cells to DNSP inhibitors, as 
shown in studies on leukemia and lung cell lines  [30] and 
various malignant neoplasms  [27] . This is particularly 
relevant for lymphomas, leukemias  [27, 29] and non-
small-cell lung carcinoma  [34, 45] . Nevertheless, chemo-
therapy regimens with pemetrexed were not effective for 
pediatric patients with medulloblastomas, ependymomas 
and high-grade gliomas  [49] , and the addition of metho-
trexate in the chemotherapeutic treatment of infratento-
rial ependymomas did not improve the response to these 
drugs  [50] . However, none of these studies assessed 
MTAP expression in the tumors. In the light of the knowl-
edge about MTAP expression, further clinical studies 
could help to elucidate the poor results of DNSP inhibi-
tors in pediatric brain tumors. Although it is a small sub-
set, patients with PAs that exhibit a loss of MTAP expres-
sion could potentially benefit from treatment with DNSP 
inhibitors, especially when lesions are recurrent or un-
achievable to surgical resection.
 To conclude, understanding the role of MTAP in an 
indolent neoplasm, such as PA, may help to uncover the 
mechanisms by which the activation of MAPK leads to 
senescence, instead of stimulating cell proliferation in 
these tumors. Additional studies, with larger cohorts, 
comparisons with other glioma subtypes and correlations 
with different molecular mechanisms of MAPK activa-
tion are needed to confirm and extend our findings and 
to elucidate the role of MTAP in gliomagenesis.
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 Table 2.  MTAP expression according to the location of the tumor
 MTAP score
neg ative ≤3 ≥4 total
Cerebellum 0 5 31 36
Brain stem 0 1 3 4
Medullary 0 0 5 5
Suprasellar 0 0 6 6
Optic pathways 0 0 4 4
Cerebral hemispheres 3 1 10 14
Total 3 7 59 69
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